Kutatási jelek – Signal Engine

• Combination treatments for myelofibrosis in JAK inhibitor‑naive patients: evidence, rationale, and clinical direction. — Myelofibrosis
• Single agent selinexor is active in patients with myelofibrosis refractory or intolerant to JAK inhibitors — Myelofibrosis
• Dynamic on-treatment prognosis refinement in molecularly defined lower-risk myelofibrosis — Melanoma
• Targeted treatment of anemia in myelofibrosis and the impact of JAK inhibitors — Myelofibrosis
• Distinct clinical, molecular, and treatment response profiles in primary and secondary myelofibrosis: a single‑center retrospective study — Myelofibrosis
• A CT-based radiomics model for preoperative risk stratification of gastrointestinal stromal tumors — Gastrointestinal stromal tumor
• POIESIS: a phase III study of add‑on navtemadlin in JAK inhibitor‑naïve myelofibrosis patients with a suboptimal response to ruxolitinib — Myelofibrosis
• Establishment and genomic validation of novel patient-derived xenograft models for drug discovery in gastrointestinal stromal tumor — Gastrointestinal stromal tumor
• Integrating CT radiomics and morphologic features for preoperative risk stratification of gastrointestinal stromal tumours — Head and neck squamous cell carcinoma
• Development of a prognostic prediction model for tumor recurrence or progression in gastrointestinal stromal tumors: integrating inflammatory blood indices with 5 mm2 versus 50 high-power field mitotic counts — Gastrointestinal stromal tumor
• Impact of neoadjuvant imatinib duration and tumor response on recurrence‑free survival in locally advanced gastrointestinal stromal tumors: a retrospective multicenter cohort study — Gastrointestinal stromal tumor
• EPHA3, upregulated in high-risk histological subtypes of gastrointestinal stromal tumor, promotes GIST progression — Gastrointestinal stromal tumor
• Disproportionality analysis of adverse events associated with tyrosine kinase inhibitors in gastrointestinal stromal tumors in the FDA adverse event reporting system — Gastrointestinal stromal tumor
• Prognostic significance of GLUT-1 in adenoid cystic carcinoma — Adenoid cystic carcinoma
• Successful management of metachronous dual primary esophageal carcinomas: first report of consecutive adenoid cystic carcinoma and squamous cell carcinoma with exceptional treatment outcome – a case report — Esophageal cancer
• Postoperative radiotherapy or chemoradiotherapy versus surgery only in non-metastatic head and neck adenoid cystic carcinoma: a retrospective analysis — Head and neck squamous cell carcinoma
• Adenoid cystic carcinoma of the thymus: a case report and literature review — Adenoid cystic carcinoma
• Development and external validation of a machine learning model for predicting overall survival in head and neck adenoid cystic carcinoma based on the SEER database and a Chinese clinical cohort — Adenoid cystic carcinoma
• Examining progression of advanced lacrimal gland adenoid cystic carcinoma — Adenoid cystic carcinoma
• Exosomal S100A9 promotes lung metastasis of adenoid cystic carcinoma via activating cancer-associated fibroblasts — Chronic lymphocytic leukemia